Tetherex Pharmaceuticals Overview

  • Founded
  • 2002

Founded
  • Status
  • Private

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $50M

  • Investors
  • 9

Tetherex Pharmaceuticals General Information

Description

Producer of medicinal drugs designed to treat thrombosis, inflammation, and tumor metastasis. The company's drugs develop novel first-in-class therapeutics targeting cell adhesion proteins in thrombotic, inflammatory, and oncologic diseases to work on the molecular mechanisms of cell adhesion and inflammation, enabling patients who suffer these afflictions to enjoy descent and long lives.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 840 Research Parkway
  • Suite 516
  • Oklahoma City, OK 73104
  • United States
+1 (405) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tetherex Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B) 06-Mar-2018 $50M 000.00 00000 Completed Clinical Trials - General
6. Debt - General 09-Oct-2015 000 000.00 Completed Clinical Trials - General
5. Later Stage VC (Series A) 09-Feb-2015 00.000 000.00 Completed Clinical Trials - General
4. Later Stage VC (Series A) 17-Sep-2012 0000 0000 000.00 Completed Clinical Trials - General
3. Angel (individual) 01-Apr-2010 0000 0000 Completed Clinical Trials - General
2. Grant 16-Jun-2009 $3.2M Completed Clinical Trials - General
1. Grant 28-Apr-2009 $300K Completed Clinical Trials - General
To view Tetherex Pharmaceuticals’s complete valuation and funding history, request access »

Tetherex Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00.0 000 000 00 000 00.000
Series A 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view Tetherex Pharmaceuticals’s complete cap table history, request access »

Tetherex Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Producer of medicinal drugs designed to treat thrombosis, inflammation, and tumor metastasis. The company's drugs develo
Drug Discovery
Oklahoma City, OK
000.00
0000 0000-00-00
00000000000 000.00

0000 0

aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. E
0000 000000000
San Diego, CA
00 As of 0000
00000
00000000 00000

00000

sequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
0000 000000000
Tucson, AZ
00 As of 0000
000.00
000 0000-00-00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tetherex Pharmaceuticals Competitors (94)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
aTyr Pharma Formerly VC-backed San Diego, CA 00 00000 00000000 00000
00000 000000 Venture Capital-Backed Tucson, AZ 00 000.00 0000000000 0 000.00
0000000 0000000000 Formerly VC-backed Boston, MA 00 00000 000000000 00000
0000000 0000000000 Venture Capital-Backed South San Francisco, CA 00 000.00 0000000000 000.00
000000 00000000000 Formerly VC-backed Boston, MA 0000 00.000 000000&0
You’re viewing 5 of 94 competitors. Get the full list »

Tetherex Pharmaceuticals Patents

Tetherex Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2009246166-B2 Anti-psgl-1 antibodies and methods of identification and use Active 15-May-2008 00000000000
AU-2009246166-A1 Anti-psgl-1 antibodies and methods of identification and use Active 15-May-2008 00000000000
CA-2724415-A1 Anti-psgl-1 antibodies and methods of identification and use Active 15-May-2008 00000000000
CA-2724415-C Anti-psgl-1 antibodies and methods of identification and use Active 15-May-2008 00000000000
EP-2291536-A4 Anti-psgl-1 antibodies and methods of identification and use Inactive 15-May-2008 C07K16/2896
To view Tetherex Pharmaceuticals’s complete patent history, request access »

Tetherex Pharmaceuticals Executive Team (9)

Name Title Board Seat Contact Info
Scott Rollins Ph.D Chief Executive Officer & Chairman
Russell Rother Ph.D President, Chief Operating Officer & Board Member
Rodger McEver MD Co-Founder & Board Member
Richard Cummings Ph.D Co-Founder
Richard Alvarez Vice President, Operations & Research
You’re viewing 5 of 9 executive team members. Get the full list »

Tetherex Pharmaceuticals Board Members (5)

Name Representing Role Since
David Keiser Self Board Member 000 0000
Philip Jones MD Self Board Member 000 0000
Rodger McEver MD Tetherex Pharmaceuticals Co-Founder & Board Member 000 0000
Scott Rollins Ph.D Tetherex Pharmaceuticals Chief Executive Officer & Chairman 000 0000
Todd Foley MPM Capital Board Member 000 0000
To view Tetherex Pharmaceuticals’s complete board members history, request access »

Tetherex Pharmaceuticals Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Mayo Clinic Ventures Venture Capital Minority 000 0000 000000 0
Philip Jones Angel (individual) Minority 000 0000 000000 0
i2E Venture Capital Minority 000 0000 000000 0
MPM Capital Venture Capital Minority 000 0000 000000 0
Oklahoma Life Science Fund Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »